July 13, 2022 -- The National Cancer Institute (NCI) has awarded $4.2 million over five years to Mount Sinai researchers to establish a Proteogenomic Data Analysis Center for identifying potential cancer biomarkers and drug targets, new insights into cancer biology, and bioinformatics tools to enable advanced exploration and discovery using cancer-related datasets.
Proteogenomics, a biological research field that combines proteomics, genomics, and transcriptomics, is the focus of the new center. Avi Ma'ayan, PhD, professor of pharmacological sciences and director of the Mount Sinai Center for Bioinformatics, and Pei Wang, PhD, professor of genetic and genomic sciences, are the lead investigators for the new center.
Ma'ayan and Wang will "leverage their expertise in statistics/biostatistics, machine learning, data integration, systems pharmacology, and proteomics data modeling to further understand the proteogenomic complexity of tumors," according to Mount Sinai's announcement.
Mount Sinai is one of NCI's 14 Clinical Proteomic Tumor Analysis Consortium centers in the U.S., which will make available to the public the data generated and tools developed with the goal of helping advance and accelerate cancer research.